
Annual report 2020
added 08-19-2023
Titan Medical EBITDA 2011-2026 | TMDI
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Titan Medical
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -31 M | 4.15 M | -59.3 M | - | - | -27.8 M | -42.6 M | -14.8 M | -8.83 M | -7.72 M | -15.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.15 M | -59.3 M | -22.6 M |
Quarterly EBITDA Titan Medical
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | -12.1 M | - | -14.1 M | -2.02 M | -11.8 M | - | -4.52 M | 7.46 M | -1.73 M | - | -18.5 M | -21.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.46 M | -21.2 M | -8.72 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
EDAP TMS S.A.
EDAP
|
-18 M | $ 3.22 | -2.57 % | $ 121 M | ||
|
Align Technology
ALGN
|
753 M | $ 189.61 | -0.56 % | $ 14.2 B | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | ||
|
AdaptHealth Corp.
AHCO
|
473 M | $ 12.8 | 0.55 % | $ 1.73 B | ||
|
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | ||
|
BioSig Technologies
BSGM
|
-67.6 M | - | 37.08 % | $ 85.7 M | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
-53.2 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
-24.1 M | - | 1.37 % | $ 20.5 M | ||
|
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | ||
|
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | ||
|
Cytosorbents Corporation
CTSO
|
-13.5 M | $ 0.63 | -3.04 % | $ 39.2 M | ||
|
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | ||
|
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | ||
|
ClearPoint Neuro
CLPT
|
-23.4 M | $ 11.78 | 9.58 % | $ 334 M | ||
|
Dynatronics Corporation
DYNT
|
-1.97 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
-106 M | - | - | $ 10.2 M | ||
|
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | ||
|
Electromed
ELMD
|
10.7 M | $ 26.39 | 3.57 % | $ 223 M | ||
|
Second Sight Medical Products
EYES
|
-27.1 M | - | -0.97 % | $ 54.4 M | ||
|
GBS
GBS
|
-9.67 M | - | -0.57 % | $ 7.12 M | ||
|
Globus Medical
GMED
|
757 M | $ 94.87 | 0.52 % | $ 12.8 B | ||
|
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | ||
|
Helius Medical Technologies
HSDT
|
-12.4 M | $ 2.16 | 4.85 % | $ 1.31 M | ||
|
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M | ||
|
Butterfly Network
BFLY
|
-65.5 M | $ 5.33 | 3.5 % | $ 1.13 B | ||
|
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | ||
|
OrthoPediatrics Corp.
KIDS
|
-18.1 M | $ 16.19 | -0.12 % | $ 380 M | ||
|
LivaNova PLC
LIVN
|
228 M | $ 64.2 | -1.45 % | $ 3.5 B | ||
|
LENSAR
LNSR
|
-21 M | $ 5.09 | -3.23 % | $ 60.9 M | ||
|
Pulmonx Corporation
LUNG
|
-52.6 M | $ 1.27 | -0.78 % | $ 51.7 M | ||
|
Delcath Systems
DCTH
|
898 K | $ 10.84 | 1.88 % | $ 388 M | ||
|
IRIDEX Corporation
IRIX
|
-2.05 M | $ 1.06 | 0.95 % | $ 18 M | ||
|
CONMED Corporation
CNMD
|
120 M | $ 38.34 | 2.24 % | $ 1.19 B | ||
|
Inspire Medical Systems
INSP
|
64.9 M | $ 56.31 | -0.07 % | $ 1.65 B | ||
|
Integer Holdings Corporation
ITGR
|
352 M | $ 86.02 | 1.37 % | $ 2.99 B | ||
|
PAVmed
PAVM
|
-21.7 M | $ 9.0 | -1.85 % | $ 6.03 M | ||
|
Invacare Corporation
IVC
|
-65 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
1.42 B | $ 84.15 | 5.56 % | $ 49.2 B | ||
|
MiMedx Group
MDXG
|
78.8 M | $ 3.43 | 2.39 % | $ 507 M | ||
|
Nevro Corp.
NVRO
|
-118 M | - | - | $ 217 M | ||
|
Myomo
MYO
|
-13.5 M | $ 0.82 | 5.52 % | $ 34.3 M | ||
|
TELA Bio
TELA
|
-33.1 M | $ 0.7 | 12.54 % | $ 32.9 M | ||
|
Cutera
CUTR
|
-148 M | - | -10.19 % | $ 1.99 M |